


<u>Study name</u>	<u>Year</u>	<u>Adjuvant</u>	<u>Statistics for each study</u>		
			<u>Hazard ratio</u>	<u>Lower limit</u>	<u>Upper limit</u>
Adler (stage I-III)	1987	BCG	3.45	0.48	24.94
Adler (stage IV)	1987	BCG	2.33	0.75	7.25
Gray (stage B)	1989	BCG	1.01	0.64	1.59
Gray (stage C)	1989	BCG	0.97	0.59	1.61
Hoover (colon)	1993	BCG	2.83	1.13	7.08
Hoover (rectal)	1993	BCG	1.13	0.50	2.57
Galligioni	1996	BCG	0.69	0.35	1.36
Harris	2000	BCG	1.05	0.76	1.44
Uyl-de Groot (stage II)	2005	BCG	1.85	0.97	3.52
Uyl-de Groot (stage III)	2005	BCG	0.86	0.40	1.81
BCG OVERALL			1.15	0.91	1.46
Souter (stage I)	1981	C Parvum	0.64	0.26	1.61
Souter (stage II)	1981	C Parvum	1.32	0.46	3.76
C Parvum OVERALL			0.88	0.44	1.76
Kuang	2004	GMCSF	14.29	1.98	103.01
Bota	2018	GMCSF	1.75	0.40	7.78
Rocconi (BRCA mutant)	2020	GMCSF	0.62	0.17	2.30
Rocconi (BRCA wt)	2020	GMCSF	2.03	1.00	4.13
GMCSF OVERALL			1.99	0.75	5.25
Schulze (colon)	2009	NDV	3.30	1.02	10.64
Schulze (rectal)	2009	NDV	1.54	0.55	4.28
NDV OVERALL			2.14	0.99	4.62



Supplemental Figure 3. Overall Survival based on adjuvant.